NCT00449111终止3 期
An Open Label Study to Assess the Efficacy, Safety and Tolerability of COZAAR Plus (Losartan Potassium 50mg/Hydrochlorothiazide 12.5mg) Possibly Titrated up to COZAAR Plus-F (Losartan Potassium 100mg/Hydrochlorothiazide 25mg) in Patients With Essential Hypertension
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 终止
- 入组人数
- 11
- 主要终点
- Change of diastolic blood pressure after 6 weeks of treatment with cozaar plus
研究概览
简要总结
Evaluate blood pressure after 6 weeks of treatment with COZAAR plus.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient treated with valsartan 80mg or irbesartan 150mg or vandesartan 8mg for at least 4 weeks prior to visit 1
- •Patient with systolic blood pressure between 140 to 159 mmhg and diastolic pressure between 90 to 99mmhg taken at visit 1
排除标准
- •History of angina pectoris that has not been stabilized in the past 6 weeks
- •History of clinically significant abnormal lab results or diseases
- •Myocardial infarction within the past 6 months
- •Stroke in the past 6 months
结局指标
主要结局
Change of diastolic blood pressure after 6 weeks of treatment with cozaar plus
次要结局
未报告次要终点
研究者
相似试验
已完成
3 期
Safety and Tolerability and Efficacy of LCZ696 in Japanese Hypertensive Patients With Renal DysfunctionHypertension With Renal DysfunctionNCT01593787Novartis Pharmaceuticals32
撤回
3 期
Study of the Efficacy and Safety of LCZ696 Alone and in Combination With Amlodipine in Patients With HypertensionHypertensionNCT01865188Novartis Pharmaceuticals
已完成
4 期
Dose Titration of Lisinopril in Children Aged 1 to 18 Years With Primary or Secondary HypertensionPrimary HypertensionSecondary HypertensionNCT02184858University Ghent13
已完成
3 期
Efficacy and Safety of SPA100 (Fixed-dose Combination of Aliskiren/Amlodipine) in Patients With Essential HypertensionEssential HypertensionNCT01237223Novartis1,342
已完成
3 期
Safety and Tolerability and Efficacy of LCZ696 in Japanese Severe Hypertensive PatientsSevere HypertensionNCT01646671Novartis Pharmaceuticals35